drugset / Trial / NCT00577720
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
RandomizedParallel-groupDouble-blindTreatment
Summary
To compare the efficacy 50 mg delayed-release risedronate tablet, dosed immediately after breakfast, to a 35 mg immediate-release tablet, administered according to labeling instructions.
Timeline
- Start
- 2006-07
- Primary completion
- 2007-01
- Completion
- 2007-01
Outcome
Met primary endpoint
registry Ratio (LS Mean 35 mg DRFB/35 mg IRBB) 1.437 (90% CI 1.091 to 1.964) NCT00577720 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risedronate | Small molecule | 35 mg | Oral |
| Subject | Risedronate | Small molecule | 50 mg | Oral |
Indications
No indication recorded.